Gao, NJ
Dayuan Gao, East Brunswick, NJ US
Patent application number | Description | Published |
---|---|---|
20110268803 | LUNG TARGETING DUAL DRUG DELIVERY SYSTEM - The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases. | 11-03-2011 |
20140010862 | MULTIFUNCTIONAL BIODEGRADABLE PEG NANOCARRIER-BASED HYDROGELS FOR PREVENTING HIV TRANSMISSION - A multifunctional polyethylene glycol-based hydrogel that includes a multi-arm polyethylene glycol cross-linking unit covalently bound to at least four multi-arm polyethylene glycol nanocarrier units, wherein each nanocarrier unit includes an agent coupled to the nanocarrier unit and each agent is selected from pH-lowering agents, bioadhesion agents, microbicidal-spermicidal agents, and agents that inhibit free and cell-associated HIV binding, provided that each nanocarrier unit comprises a different agent. | 01-09-2014 |
He Gao, Plainsboro, NJ US
Patent application number | Description | Published |
---|---|---|
20080213418 | ALIGN-TRANSFER-IMPRINT SYSTEM FOR IMPRINT LITHOGRPHY - An imprint system for imprint lithography comprises an alignment subsystem and an imprint subsystem. The mask (mold) and the wafer for imprinting (substrate) are align on the alignment subsystem and contacted to each other to form a mask/wafer set. The mask/wafer set is then transferred onto the imprint subsystem while alignment is maintained. The mask/wafer set is then imprinted on the imprint subsystem. During transfer, the mask/wafer set can be held in alignment by surface. The surface adhesion can be enhanced by local pressing, local heating, or both. Alternatively, the mask/wafer set can be held in alignment by clamping. Advantageously, the imprinting is effected by fluid pressure imprinting. | 09-04-2008 |
Hong Gao, Belle Mead, NJ US
Patent application number | Description | Published |
---|---|---|
20080200541 | Benzofuranyl Alkanamine Derivatives and Uses Thereof - Compounds of formula I or pharmaceutically acceptable salts thereof are provided: | 08-21-2008 |
20090082434 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same - Compounds of Formula 1 or pharmaceutically acceptable salts thereof are provided: | 03-26-2009 |
Ji Gao, Cranbury, NJ US
Patent application number | Description | Published |
---|---|---|
20110269139 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO EPIDERMAL GROWTH FACTOR RECEPTOR MODULATORS - The present invention provides methods useful for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, and diagnostic methods and kits thereof. | 11-03-2011 |
Jieming Gao, New Brunswick, NJ US
Patent application number | Description | Published |
---|---|---|
20120183578 | POLYETHYLENE GLYCOL-BASED DENDRONS - The instant invention relates to polyethylene glycol-based dendrons, otherwise known as PEGtide dendrons, compositions thereof and methods of use. | 07-19-2012 |
20120183621 | SYNERGISTIC COMBINATIONS TO REDUCE PARTICLE DOSE FOR TARGETED TREATMENT OF CANCER AND ITS METASTASES - Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis. | 07-19-2012 |
Julia Zh Gao, Plainsboro, NJ US
Patent application number | Description | Published |
---|---|---|
20080275009 | ORAL ADMINISTRATION OF N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-1,3-THIAZOLE-5-CARBOXAMIDE AND SALTS THEREOF - Disclosed are a method of treating cancer and/or other proliferative diseases comprising orally administering N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof, and pharmaceutical compositions comprising N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof. Also disclosed are N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide salts, as well as crystalline forms thereof. | 11-06-2008 |
20130122093 | FORMULATIONS OF A SRC/ABL INHIBITOR - The invention relates to pharmaceutical compositions of ′N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, and to methods of using the pharmaceutical compositions in the treatment of oncological and immunological disorders | 05-16-2013 |
Jun Gao, Livingston, NJ US
Patent application number | Description | Published |
---|---|---|
20130067791 | ELECTRONIC FISHING LURE WITH TOUCH CONTROL - The present invention is a fishing lure which utilizes an onboard controller to control one or a series of light (multicolor/mono color) sources so as to enhance fishing lure's color and visibility for all light conditions a user may encounter during fishing. The controller unit, power source, light sources of the present invention are all contained in a sealed housing. The switching mechanism, controlling mechanism, and charging mechanism are all multiplexed into two electrical contact points. The electrodes are embedded in the electronic body parts and embedded in the housing therefore eliminating water leaking through active seams or openings. The present invention further provides a safe and effective charging mechanism which involves an electronic component barrier to prevent current from flowing from one electrical contact point to the other during charging. | 03-21-2013 |
20150135469 | DUSTPAN - An upright dustpan is disclosed which allows a user to open and close a door of a dust collecting compartment through a trigger on the handle. A trigger activates an actuating arm, which in turn causes the movement of an actuating pin that is connected to an external arm which opens the compartment door. The movement of the actuating pin may be lateral or rotational, providing different movement to the external arm. | 05-21-2015 |
Junguo Gao, Robbinsville, NJ US
Patent application number | Description | Published |
---|---|---|
20130204828 | System and Method for Enhanced, Flexible Mail Address Validation and Hygiene - A method for reformatting and updating mailing addresses in a mailing address database to maximize postal rate discounts while enforcing a set of business rules dictating the circumstances under which individual mailing addresses may be changed and for setting a disposition status for each mailing address based on the application of the business rules and the outcome of process to reformat and update the mailing addresses. | 08-08-2013 |
Milan Gao, Columbus, NJ US
Patent application number | Description | Published |
---|---|---|
20150086552 | BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 03-26-2015 |
Min Gao, Montvale, NJ US
Patent application number | Description | Published |
---|---|---|
20130195878 | ANTI-ASIC1 ANTIBODIES AND USES THEREOF - The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders. | 08-01-2013 |
20140056907 | ANTI-ASIC1 ANTIBODIES AND USES THEREOF - The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. According to certain embodiments, the antibodies of the invention are selective for ASIC1 and do not bind other acid-sensing ion channels in the absence of ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders. | 02-27-2014 |
Min Gao, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20080213817 | Enhancement of Th2-Dependent and Inflammatory Response - The present invention relates to altering the levels of Th2 cytokine production, and in particular, biasing the cytokine expression profile towards Th2 cytokine production through mitogen-activated protein kinase/ERK kinase kinase 1 (MEKK1), the screening of agents that increase Th2 cytokine production, and the treatment of Th1 associated autoimmune diseases in vivo. In one embodiment, the present invention relates to agents including but not limited to reducing the activity of MEKK1, leading to increased levels of Th2 cytokine production. | 09-04-2008 |
Qui Gao, Franklin Park, NJ US
Patent application number | Description | Published |
---|---|---|
20140275101 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDA- ZIN-3-AMINE - The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form. | 09-18-2014 |
Song Gao, East Brunswick, NJ US
Patent application number | Description | Published |
---|---|---|
20140141082 | Compositions Containing Enriched Natural Crocin and/or Crocetin, and Their Therapeutic or Nutraceutical Uses - The invention relates to unique compositions containing enriched and purified natural crocin and/or crocetin for prevention and/or treatment of cancers and other conditions and diseases. Compositions comprise mainly enriched or purified natural crocin or crocetin or combination of both and possible other active phytochemicals. A composition is used as functional food, drink, dietary supplement, or therapeutic dosage to a human orally or through other appropriate way (parenteral, percutaneous, rectal, mucosal, intranasal or topical administration). A method of natural crocin and crocetin enriching and purification is revealed. | 05-22-2014 |
Xiaolei Gao, Rahway, NJ US
Patent application number | Description | Published |
---|---|---|
20150353570 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders. | 12-10-2015 |
Xiaolei Gao, Scotch Plains, NJ US
Patent application number | Description | Published |
---|---|---|
20090118284 | Novel compounds that are ERK inhibitors - Disclosed are the ERK inhibitors of formula 1.0: | 05-07-2009 |
Xiaolei Gao, Kenilworth, NJ US
Patent application number | Description | Published |
---|---|---|
20110189192 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS - Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. | 08-04-2011 |
Xiaolei Gao, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20110038876 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS - Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. | 02-17-2011 |
20130096084 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS - The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same. | 04-18-2013 |
20130172341 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS - Disclosed are the ERK inhibitors of Formula (I): (Formula (I)) and the pharmaceutically acceptable salts thereof. All substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (I). | 07-04-2013 |
20130237518 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS - Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1). | 09-12-2013 |
20140206681 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I | 07-24-2014 |
20140221333 | BTK INHIBITORS - Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders. | 08-07-2014 |
20150353570 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders. | 12-10-2015 |
Xingtao Gao, Holmdel, NJ US
Patent application number | Description | Published |
---|---|---|
20120156116 | Process For Metal Recovery From Catalyst Waste - A method for recovering rare earth metals from zeolite-containing waste FCC catalysts comprises an acid leaching step to remove the rare earth metals from the catalyst to form a leachate containing dissolved rare earth metals and separating the rare earth metals from the leachate such as by precipitation. | 06-21-2012 |
20130252802 | IN-SITU PRODUCED Y-FAUJASITE FROM KAOLIN-DERIVED, PRE-SHAPED PARTICLES AND THE METHOD OF PREPARATION AND TEH USE THEREOF - A zeolite-containing fixed bed catalyst is formed by pre-shaping a mixture of a reactive aluminum-containing component and a matrix component into pre-shaped particles, and contacting the pre-shaped particles with a reactive liquid containing a silicate for a sufficient time and temperature to form an in-situ zeolite within the pre-shaped particles. The contacting of the pre-shaped particles and the liquid is achieved such that there is relative movement between the pre-shaped particles and the liquid. | 09-26-2013 |
20140206526 | ZSM-5 ADDITIVE ACTIVITY ENHANCEMENT BY IMPROVED ZEOLITE AND PHOSPHORUS INTERACTION - A catalytic additive comprising an intermediate pore zeolite, such as ZSM-5 is treated so as to improve propylene yields when the additive is included in a FCC catalytic inventory by first treating the zeolite with a phosphorus compound to incorporate the phosphorus in the zeolite, and mixing the P-treated zeolite with a matrix component comprising kaolin and another phosphorus-containing compound. | 07-24-2014 |
Xingtao Gao, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20110139684 | Catalyst Composition for Reducing Gasoline Sulfur Content in Catalytic Cracking Process - A sulfur reduction catalyst useful to reduce the levels of sulfur in a cracked gasoline product comprises a metal vanadate compound. The metal vanadate compound can be supported on a molecular sieve such as a zeolite in which the metal vanadate compound is primarily located on the exterior surface of the pore structure of the zeolite and on the surface of any matrix material used to bind or support the zeolite. | 06-16-2011 |
Xintao Gao, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20110243837 | Method for Making Mesoporous or Combined Mesoporous and Microporous Inorganic Oxides - A method for making a mesoporous or combined mesoporous/microporous inorganic oxide includes reacting a source of inorganic oxide with a complexing agent at a complexation temperature to provide a complex; decomposing the complex to provide a porous material precursor having an inorganic oxide framework containing at least some organic pore-forming agent; and removing the organic pore forming agent from the inorganic oxide framework by solvent extraction and/or calcination. | 10-06-2011 |
Xuerong Gao, Livingston, NJ US
Patent application number | Description | Published |
---|---|---|
20090188555 | Conductive Inks With Metallo-Organic Modifiers - A conductive ink having a glass frit, an organic medium a conductive species and one or more metallo-organic components which form metal oxides upon firing and reduce series resistance to a same or greater degree a ink that do not include metallo-organic components, is provided. Embodiments of conductive ink include metallo-organic components that include a bismuth metallo-organic component and glass frits comprising one or more of bismuth oxide, silica, boron oxide, tellurium dioxide, and combinations thereof. Embodiments of photovoltaic cells with an anti-reflection coating, gridlines formed from conductive ink incorporating one or more metallo-organic components, are also provided. | 07-30-2009 |
20090188556 | Conductive inks - A conductive ink substantially free of frit and photovoltaic cells having conductive gridlines formed from a conductive ink substantially free of glass frit are described. Conductive inks according embodiments of the present invention are adapted to adhere to the surface of a substrate and, upon firing, form a solid metal oxide phase and cause a conductive species to form an electrical conductor on the substrate. In further embodiments, the conductive ink is capable of penetrating anti-reflection coatings disposed on surfaces of substrates. In accordance with one or more embodiments, the conductive inks include a plurality of metallo-organic components which form a solid metal oxide phase upon firing and a conductive species. In other embodiments, the conductive inks include a plurality of precursors, including one or more precursors which form conductive elements upon firing or heating. | 07-30-2009 |
20100193494 | Conductive Compositions - A conductive composition having a conductive component, a glass frit component, an organic medium, a boride component and a platinum group metal component, is provided. Embodiments of the conductive composition incorporate a palladium component and boride component selected from ZrB | 08-05-2010 |
20140356524 | Nanostructure Dispersions And Transparent Conductors - A nanostructure dispersion comprising a mixture of host metallic nanostructures and metallic nanoparticles is provided. The nanostructures and nanoparticles are attracted to each other and remain attracted upon deposition of the mixture onto a substrate to form a transparent conductor. Also provided is a method of fabricating a transparent conductor. | 12-04-2014 |
Ying-Duo Gao, Holmdel, NJ US
Patent application number | Description | Published |
---|---|---|
20140206681 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I | 07-24-2014 |
20150353570 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders. | 12-10-2015 |
Ying-Duo Gao, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20090105210 | Bicyclic Pyrimidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes - The present invention is directed to novel substituted bicyclic pyrimidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 04-23-2009 |
20100317645 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS - Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes. | 12-16-2010 |
Zhan Gao, Tenafly, NJ US
Patent application number | Description | Published |
---|---|---|
20120171193 | Diagnostic and Treatment Methods for Characterizing Bacterial Microbiota in Skin Conditions - The present invention relates to methods for characterization of bacterial skin microbiota to provide diagnostic, therapeutic, and preventive measures for alleviating skin conditions. In certain embodiments, the invention relates to characterization of bacterial skin microbiota associated with psoriasis and related diagnostic, therapeutic, and preventive measures for alleviating psoriasis. These methods will be useful for detecting, diagnosing, and monitoring individuals who have or are at risk of certain skin conditions. | 07-05-2012 |
Zhinong Gao, Princeton, NJ US
Patent application number | Description | Published |
---|---|---|
20150133654 | NOVEL METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4bS,5aR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3-METHOXY-5a-((1R,5S)-3- -METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4b,5,5a,6-TETRAHYDROBENZ- O [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE - The present invention provides methods and intermediates for the preparation of (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide (formula I), including pharmaceutically acceptable salts. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 05-14-2015 |
Zhongli Gao, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20110251225 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I): | 10-13-2011 |
20110257213 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 10-20-2011 |
20110312934 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF - The invention relates to 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives of the general formula (I) where: R | 12-22-2011 |
Zhongli Gao, Flemington, NJ US
Patent application number | Description | Published |
---|---|---|
20100173897 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 07-08-2010 |
20100173898 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides of formula (I). | 07-08-2010 |
20100173908 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine ureas of formula (I). | 07-08-2010 |
20100173949 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 07-08-2010 |
20100179154 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to the 6-cycloamino-3-(pyridin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): | 07-15-2010 |
20120065234 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 03-15-2012 |
20120238757 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I): | 09-20-2012 |
20120258979 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 10-11-2012 |
20130012516 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to the 6-cycloamino-3-(pyridin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): | 01-10-2013 |
20130059838 | SUBSTITUTED N-HETEROARYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-heteroaryl tetrahydro-isoquinoline derivatives of formula (I). | 03-07-2013 |
20130059863 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-heteroaryl spirolactam bipyrrolidines of formula (I). | 03-07-2013 |
20130059874 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl spirolactam bipyrrolidines of formula (I). | 03-07-2013 |
20130059891 | SUBSTITUTED N-HETEROCYCLOALKYL BIPYRROLIDINYLPHENYL AMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives of formula (I). | 03-07-2013 |
20130065877 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides of formula (Ia) and formula (Ib). | 03-14-2013 |
20130065919 | SUBSTITUTED N-ALKYL AND N-ACYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives of formula (I). | 03-14-2013 |
20130065923 | SUBSTITUTED N-HETEROARYL BIPYRROLIDINE CARBOXAMIDES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-heteroaryl bipyrrolidine carboxamides of formula (I). | 03-14-2013 |
20140275005 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides of formula (Ia) and formula (Ib). | 09-18-2014 |
20140315923 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-heteroaryl spirolactam bipyrrolidines of formula (I). | 10-23-2014 |